Diplomat Celebrates World Hepatitis Month with National Multimedia Campaign
FLINT, Mich. – May 3, 2016 – The nation’s largest independent specialty pharmacy launches a national campaign to drive awareness of hepatitis and its impact on patients’ lives.
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis Awareness Month with a campaign to honor patients and caregivers. The company released a video of two patients who tell their personal story and encourage those at risk to get tested and begin the road to a life free of hepatitis.
National Hepatitis Awareness Month is intended to raise awareness of hepatitis C virus (HCV) and its impact on patients’ lives. HCV is an infectious disease that causes inflammation of the liver, which can diminish the liver function or cause liver failure. Some individuals with chronic C infection may develop cirrhosis, in which the liver is replaced by scar tissue, eventually preventing the liver from functioning properly. According to the U.S. Centers for Disease Control and Prevention, approximately 3.2 million Americans are infected with HCV.
“The stories of Jacque and Susy echo the true testament of Diplomat’s patient-centric focus,” said Diplomat CEO and Chairman Phil Hagerman. “At Diplomat, we’re champions for our hepatitis C patients and their support systems. We work daily to help make hepatitis C a thing of the past and are proud to stand by our patients during and after their treatment.”
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2015 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | firstname.lastname@example.org